Diamyd Medical AB

Diamyd Medical AB
About Us
Contacts
Quotes
Change country

Follow us:
Share:
Subscribe:

About Us

Diamyd Medical is a clinical-stage diabetes company active in the field of pharmaceutical development. We develop two novel disease-modifying drugs: the antigenspecific immunotherapy Diamyd® and the oral regenerative and immunomodulatory therapeutic Remygen®. A biomanufacturing facility is being set up in Umeå for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd®.

Contacts

Ulf Hannelius

CEO

Box 7349, SE-103 90 Stockholm
+46 8 661 00 26
+46 8 661 63 68
https://www.diamyd.com
press@diamyd.com

Quotes

The collected genetic and immunological insights support the possibility that we may be able to truly individualize the treatment.

Ulf Hannelius, CEO

Our top strategic priority is to prepare for a marketing application for Diamyd®

Ulf Hannelius, CEO

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Annual Report 2023/2024

Tue, Dec 03, 2024 16:30 CET

Diamyd Medical's Annual Report for the financial year 2023/2024 is now available in English. The Annual Report is attached as a PDF and is available at www.diamyd.com.

There are no items matching the current filter

There are no more items matching the current filter

About Us

Contacts

Links

Quotes

Annual Report 2023/2024

Subscribe

Media

Share

About Us

Contacts

Links

Quotes

Annual Report 2023/2024

Subscribe

Media